Αρχική World News FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or... World News FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Από Ogkologos - 8 Απριλίου, 2026 379 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Highlights Key Issues for Patients with Cancer and Their Carers... 27 Μαΐου, 2025 “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... 21 Ιουλίου, 2021 Smoking Initiation Shifting from Teens to Young Adults 6 Νοεμβρίου, 2020 FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer 15 Οκτωβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Running a cancer helpline in COVID-19: two years on the virtual... Can Artificial Intelligence Help See Cancer in New, and Better, Ways? How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After...